I certainly wasn't thinking 2017 when I got back into this. The third FDA rejection and subsequent massive dilution killed any thoughts I had of this being a home run. With a reverse split pretty much guaranteed now I'm really not prepared to throw any more money at this, especially when GTHP still doesn't make a dime in profit on the units. Your 2017 target might be ambitious unless they finally get FDA approval. GLTA.
It is what it is - the kind of financing you get when you're desperate for cash. At this point I would be delighted to just break even. Worst spec play ever.
No, maymay, you have me confused with ken and the pineapple who started this thread. You know me, I only buy on the dips. Okay, putting you back on ignore. Sleep tight.
I've done all the research on this company that I need to, skippy. Apparently the concept of shareholder value is lost on you. These people have failed on that count,. The company is sitting on a huge TSA contract and has the recent wins in Europe to their credit also and yet the stock is sitting at 78 cents today. Like McGann and Liscouski on the last conference call, you and the other pep squad posters on here ignore, and get irritated at even the mention of, the elephant in the room - the debt and the ongoing dilution. When this crew comes out and says it is a priority to get better terms on its financing and end the ongoing dilution and we're sitting at a share price more indicative of the recent contract wins, then they can start granting themselves these kind of numbers of options. Until then, I'll vote no. I'm not holding my breath though, not after the way Liscouski responded to a shareholder on the last call and then McGann said, "we gotta go" and ended the call. And now they want to increase the OS by 50,000,000 shares while offering no reason for the need to do that. Incredible.
It's very misleading of you to suggest that the current shareholder lawsuit is the reason for the current share price when it is obvious the ongoing dilution is the reason. The lawsuit was filed because the company was not in compliance with state law and only after they refused to respond to the shareholder's (Miller) repeated attempts to contact them. And by the way, the case is Miller v Bolduc, et al. Meaning Bolduc and others if you didn't know what that meant. Have a nice day.
If you're inclined to take whatever #$%$ you're handed and say 'thank you' then by all means vote yes. These people can get their options after they've earned them - and they haven't. Not when the share price has deteriorated to what it is today. And not when they send out a proxy with only one new outside director nominee on it. Not when they try to consolidate power to themselves with no one to keep them in check. If you don't like your money or any corporate governance in a company you own then go ahead and vote yes. I voted NO on every line, and one year on the exec compensation item. The stock is at 77 cents! Have a nice day.
"they are out of cash since end of last Qtr."
Not true. Do a little reading, please.
Margin on the LuViva machine is zero, GTHP's only profits come from sales of the disposables. Business model info is on their website. This sale was through a distributor so disposables margin will be lower than if it were a direct sale.
"There is the potential that later this quarter or in the third quarter to begin to expand to six additional facilities in the county"
They're now pushing this "potential" order back to Q3. This has really turned into my worst spec play ever. By a mile. Oh well, it's only money, right? I wonder if that is what Imhoff is telling himself these days.
Guided Therapeutics, a US-based health equipment manufacturer, is targeting more business in the counties, after bagging its first local contract from the Nairobi government.
The company received its first order to supply and install cancer screening equipment at Mbagathi District Hospital worth Sh3.2 million in May.
Robert Ayisi, Nairobi health services chief officers, said one machine has been installed at the hospital with more devices on the way.
“We have installed one machine at Mbagathi Hospital but we want five more,” said Dr Ayisi.
Guided Therapeutics' management said it expects bigger orders from the Kenyan market which is set to be a major contributor to its 2015 sales that are estimated to hit Sh300 million.
“We believe this is the first step to what could be a very significant order for the company based on the money that has been budgeted by Nairobi County. There is the potential that later this quarter or in the third quarter to begin to expand to six additional facilities in the county, which would require 10 to 12 units with up to 10,000 patients per month being screened,” said Guided Therapeutics chief executive Gene Cartwright in a statement.
The company estimates there are some 1.5 million women in Nairobi eligible to use its devices for early screening of cervical cancer.
More sales are expected in other counties and the entire region.
“Our partner, Stem World Enterprises, is optimistic that the screening programme will be expanded in 2015 and in turn should support inroads in other parts of the developing world. Nairobi County is just one of 47 counties in Kenya and what Kenya’s capital does is often followed elsewhere in the country and in East Africa,” said Mr Cartwright.
Sperzel was a good hire as CEO, he follows through on things. His apology on the recent call for not having hired the last sales rep yet said a lot about his character. I think we see steady SP appreciation for the remainder of 2015. GL.
ki2002: I hope your last reply wasn't to me. I've been trying to bring attention to the debt issue here for a long time, certainly long before someone pointed it out to you on iHub recently...long before you were bragging about buying all those 78's, 77's, 76's... Have a nice day.
Anyone can add up the shares from the filings. Have a nice life, putting you on ignore with your shillmate, malcontent.
How is selling at a 900% profit stupid? They get shares at .08 for interest due, then sell them at .70. Read that back slowly if you need to in order to understand it. They can't hold the shares because their ownership cannot exceed 4.99%. Read the 10-Q. Have a nice day.
So DMRJ isn't selling? That's a lie? The item from the 10-Q is a lie also?
Saw this on the iHub board. Faupel is going to visit the Kenya distributor, hopefully to move the sales process along.
Google, "facebook Stem World Enterprises - Nairobi, Kenya"
A CEO that fields calls/emails from shareholders rather than having an IR contact handle that task shouldn't be a CEO. Okay, if Imhoff calls, take that call. But anyone else should get the IR contact. The whole "not-approvable" conversation he had with shareholders via email was ridiculous and in retrospect probably a good cue to sell. Unfortunately, I believed too much in the technology here (it is a great product) and ignored the incompetence of the leadership. I have to wonder if we might see a new CEO soon.
The $18,000 cash number is a red herring. Author did minimal research - they brought in a $720,000 investment since the end of the Q. Amazing, and rather sad given the positive impact their technology could have in saving lives, that they brought in a new CEO only to repeat the same failed approach to the FDA for a third time.